158 related articles for article (PubMed ID: 20942912)
41. Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas.
Aigner T; Müller S; Neureiter D; Illstrup DM; Kirchner T; Björnsson J
Cancer; 2002 Apr; 94(8):2273-81. PubMed ID: 12001127
[TBL] [Abstract][Full Text] [Related]
42. How safe is curettage of low-grade cartilaginous neoplasms diagnosed by imaging with or without pre-operative needle biopsy?
Brown MT; Gikas PD; Bhamra JS; Skinner JA; Aston WJ; Pollock RC; Saifuddin A; Briggs TW
Bone Joint J; 2014 Aug; 96-B(8):1098-105. PubMed ID: 25086127
[TBL] [Abstract][Full Text] [Related]
43. DNA flow cytometric analysis of chest-wall chondroma and chondrosarcoma.
Shih CS; Wang LS; Yang SS; Fahn HJ; Wu LH; Chen WY; Huang MH
Scand J Thorac Cardiovasc Surg; 1996; 30(3-4):157-61. PubMed ID: 8976036
[TBL] [Abstract][Full Text] [Related]
44. The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors.
He L; Yang Z; Zhou J; Wang W
Clin Transl Oncol; 2015 Jun; 17(6):438-45. PubMed ID: 25387569
[TBL] [Abstract][Full Text] [Related]
45. Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.
Calabuig-Fariñas S; Benso RG; Szuhai K; Machado I; López-Guerrero JA; de Jong D; Peydró A; San Miguel T; Navarro L; Pellín A; Llombart-Bosch A
Pathol Oncol Res; 2012 Oct; 18(4):793-802. PubMed ID: 22350793
[TBL] [Abstract][Full Text] [Related]
46. Expression of MMP-9 decreases metastatic potential of Chondrosarcoma: an immunohistochemical study.
Malcherczyk D; Heyse TJ; El-Zayat BF; Kunzke V; Moll R; Fuchs-Winkelmann S; Paletta JRJ
BMC Musculoskelet Disord; 2018 Jan; 19(1):9. PubMed ID: 29316907
[TBL] [Abstract][Full Text] [Related]
47. Re: MR differentiation of low-grade chondrosarcoma from enchondroma.
Yildiz S; Boyaci N; Karakas E; Dokumaci DS
Clin Imaging; 2013; 37(6):1149. PubMed ID: 23916243
[No Abstract] [Full Text] [Related]
48.
Annovazzi A; Anelli V; Zoccali C; Rumi N; Persichetti A; Novello M; Sciuto R; Bertoni F; Ferraresi V; Biagini R
Ann Nucl Med; 2019 Nov; 33(11):813-821. PubMed ID: 31396797
[TBL] [Abstract][Full Text] [Related]
49. Can imaging criteria distinguish enchondroma from grade 1 chondrosarcoma?
Crim J; Schmidt R; Layfield L; Hanrahan C; Manaster BJ
Eur J Radiol; 2015 Nov; 84(11):2222-30. PubMed ID: 26220916
[TBL] [Abstract][Full Text] [Related]
50. Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma.
Qiu W; David D; Zhou B; Chu PG; Zhang B; Wu M; Xiao J; Han T; Zhu Z; Wang T; Liu X; Lopez R; Frankel P; Jong A; Yen Y
Am J Pathol; 2003 Jun; 162(6):1961-74. PubMed ID: 12759252
[TBL] [Abstract][Full Text] [Related]
51. Chondrosarcoma of the thumb arising from a solitary enchondroma.
Peiper M; Zornig C
Arch Orthop Trauma Surg; 1997; 116(4):246-8. PubMed ID: 9128784
[TBL] [Abstract][Full Text] [Related]
52. F-18 FDG PET differentiation of benign from malignant chondroid neoplasms: a systematic review of the literature.
Subhawong TK; Winn A; Shemesh SS; Pretell-Mazzini J
Skeletal Radiol; 2017 Sep; 46(9):1233-1239. PubMed ID: 28608242
[TBL] [Abstract][Full Text] [Related]
53. Immunohistochemical study of bone GLA protein in primary bone tumors.
Iwasaki R; Yamamuro T; Kotoura Y; Okumura H; Kasai R; Nakashima Y
Cancer; 1992 Aug; 70(3):619-24. PubMed ID: 1320449
[TBL] [Abstract][Full Text] [Related]
54. Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis.
Nakagawa SA; Lopes A; Lopes de Carvalho A; Rossi BM; Werneck da Cunha I; Soares FA; Chung WT; Alves LA
J Bone Joint Surg Am; 2010 Jul; 92(8):1738-46. PubMed ID: 20660237
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic relevance of the immunohistochemical detection of growth factors in benign and malignant cartilaginous tumors.
Falcone G; Rossi ED; Maccauro G; de Santis V; Rosa MA; Capelli A; Fadda G
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):334-40. PubMed ID: 16932026
[TBL] [Abstract][Full Text] [Related]
56. The diagnosis and grading of chondrosarcoma of bone: a combined cytologic and histologic approach.
Sanerkin NG
Cancer; 1980 Feb; 45(3):582-94. PubMed ID: 6928110
[TBL] [Abstract][Full Text] [Related]
57. Quantitative SPECT/CT for differentiating between enchondroma and grade I chondrosarcoma.
Choi WH; Han EJ; Chang KB; Joo MW
Sci Rep; 2020 Jun; 10(1):10587. PubMed ID: 32601314
[TBL] [Abstract][Full Text] [Related]
58. PAS inclusions, immunoreactive tenascin and proliferative activity in low-grade chondrosarcomas.
Ranty ML; Michot C; Le Pessot F; Hellot MF; Biga N; Dujardin FH; Simonet J; Billerey C; Metayer J
Pathol Res Pract; 2003; 199(1):29-34. PubMed ID: 12650515
[TBL] [Abstract][Full Text] [Related]
59. Type II collagen, but not aggrecan expression, distinguishes clear cell chondrosarcoma and chondroblastoma.
Söder S; Oliveira AM; Inwards CY; Müller S; Aigner T
Pathology; 2006 Feb; 38(1):35-8. PubMed ID: 16484006
[TBL] [Abstract][Full Text] [Related]
60. Chondrosarcoma of the ring finger: a case report and review of the literature.
Hatori M; Watanabe M; Kotake H; Kokubun S
Tohoku J Exp Med; 2006 Mar; 208(3):275-81. PubMed ID: 16498237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
